In:
Canadian Journal of Physiology and Pharmacology, Canadian Science Publishing, Vol. 80, No. 5 ( 2002-05-01), p. 482-488
Abstract:
SSR 146977 is a potent and selective antagonist of the tachykinin NK 3 receptor. In Chinese hamster ovary cells expressing the human tachykinin NK 3 receptor, SSR 146977 inhibited the binding of radioactive neurokinin B to NK 3 receptors (K i = 0.26 nM), senktide (10 nM) induced inositol monophosphate formation (IC 50 = 7.813 nM), and intracellular calcium mobilization (IC 50 = 10 nM). It antagonized [MePhe 7 ]neurokinin B induced contractions of guinea pig ileum (pA 2 = 9.07). Senktide (30 nM) induced firing rate increase of noradrenergic neurons in the guinea pig locus coeruleus and dopaminergic neurons in the guinea pig substantia nigra was also blocked by SSR 146977 (50 and 100 nM, respectively). In vivo, in the respiratory system, SSR 146977 inhibited bronchial hyperresponsiveness to acetylcholine, bronchial microvascular permeability hypersensitivity to histamine (doses of 0.11 mg/kg i.p.), and cough (doses of 0.031 mg/kg i.p.) provoked by citric acid in guinea pigs. In the central nervous system, SSR 146977 inhibited turning behaviour (ID 50 = 0.2 mg/kg i.p. and 0.4 mg/kg p.o.) and prevented the decrease of locomotor activity (10 and 30 mg/kg i.p) mediated by the stimulation of NK 3 receptors in gerbils. In guinea pigs, SSR 146977 antagonized senktide-induced acetylcholine release in the hippocampus (0.3 and 1 mg/kg i.p) and norepinephrine release in the prefrontal cortex (0.3 mg/kg i.p.). It also prevented haloperidol-induced increase of the number of spontaneously active dopamine A10 neurons (1 and 3 mg/kg i.p.).Key words: SSR 146977, tachykinin NK 3 receptor, neurokinin B, antagonist.
Type of Medium:
Online Resource
ISSN:
0008-4212
,
1205-7541
Language:
English
Publisher:
Canadian Science Publishing
Publication Date:
2002
detail.hit.zdb_id:
2004356-9
